¶ Overview
Sleep architecture disruption is a core and early feature of both corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Unlike the prominent REM sleep behavior disorder (RBD) seen in synucleinopathies, 4R tauopathies like CBS and PSP are characterized by progressive disruption across all sleep stages, with particularly severe loss of slow-wave sleep (N3), reduced REM sleep percentage, and marked sleep fragmentation. These abnormalities reflect the underlying tau pathology affecting brainstem sleep-wake regulatory centers, the hypothalamus, basal ganglia, and subcortical white matter[1][2].
The bidirectional relationship between sleep architecture disruption and tau pathology makes sleep optimization a critical therapeutic target. Glymphatic clearance — which operates primarily during slow-wave sleep — is impaired when N3 is reduced, creating a feedforward loop where tau pathology disrupts sleep and poor sleep accelerates tau accumulation[3].
¶ Sleep Stage Abnormalities
¶ CBS Sleep Architecture
Polysomnographic studies in CBS reveal characteristic patterns across all sleep stages[1:1][4]:
N1 (Light Sleep):
- Percentage: Elevated to 15-30% (normal: 5-10%)
- This increase reflects difficulty maintaining sleep and frequent transitions from deeper stages
- Prolonged sleep latency contributes to elevated N1 percentage
- EEG shows increased alpha activity during N1, suggesting cortical hyperarousal
N2 (Sleep Spindles and K-Complexes):
- Percentage: Moderately reduced to 35-45% (normal: 45-55%)
- Sleep spindle density is reduced, correlating with thalamic involvement
- K-complexes are preserved but less frequent
- Loss of sleep spindle coherence reflects corticothalamic circuit disruption
N3 (Slow-Wave Sleep / Deep Sleep):
- Percentage: Severely reduced to 5-15% (normal: 15-25%)
- This is the most dramatic abnormality and the most therapeutically relevant
- N3 reduction correlates with disease duration and cortical tau burden[5]
- Reduced N3 impairs glymphatic clearance and memory consolidation
- EEG shows reduced delta power, fragmented slow waves, and interhemispheric asymmetry
REM Sleep:
- Percentage: Reduced to 10-20% (normal: 20-25%)
- REM latency may be shortened or normal depending on subtype
- REM sleep without atonia (RSWA) occurs in 30-50% of CBS patients but is less severe than in synucleinopathies[6]
- Loss of atonia may be partial, manifesting as chin EMG elevation without complex motor activity
- REM density and phasic events are often reduced
¶ PSP Sleep Architecture
PSP shows similar but often more severe sleep architecture abnormalities[2:1][7]:
| Stage | Normal % | CBS % | PSP % | Clinical Consequence |
|---|---|---|---|---|
| N1 | 5-10% | 15-30% | 20-35% | Sleep fragmentation, cortical arousal |
| N2 | 45-55% | 35-45% | 30-40% | Reduced spindle density |
| N3 | 15-25% | 5-15% | 3-10% | Impaired glymphatic clearance |
| REM | 20-25% | 10-20% | 8-18% | Reduced memory consolidation |
PSP patients typically show:
- Severe N3 reduction: More pronounced than in CBS
- Marked sleep fragmentation: More awakenings per hour than CBS
- Reduced sleep efficiency: Often below 65% (normal: >85%)
- Earlier sleep onset: Advanced sleep phase in many patients
- Frequent transitions: Stage shifts every 2-5 minutes on average
¶ Sleep Efficiency and Continuity
| Metric | Normal | CBS | PSP |
|---|---|---|---|
| Total sleep time | 360-420 min | 200-320 min | 180-300 min |
| Sleep efficiency | >85% | 55-75% | 50-70% |
| Wake after sleep onset (WASO) | <60 min | 90-180 min | 120-200 min |
| Sleep latency | <20 min | 30-60 min | 30-90 min |
| Number of awakenings | <10 | 15-30 | 20-40 |
¶ EEG Biomarkers of Disease Progression
¶ Quantitative EEG Findings
Sleep EEG provides objective biomarkers for disease severity and progression[4:1]:
NREM Sleep EEG:
- Delta power reduction: Correlates with cortical tau burden on PET
- Sleep spindle deficits: Reduced amplitude and frequency; spatial distribution altered
- Alpha intrusion: Waking-level alpha during N2, reflecting cortical hyperarousal
- Slow oscillation disruption: Impaired alternation between UP and DOWN states
REM Sleep EEG:
- Reduced REM density: Fewer eye movements per minute
- Impaired atonia: Elevated chin EMG during REM
- Theta band changes: Altered theta coherence in limbic regions
¶ EEG Biomarkers Table
| EEG Feature | Normal | CBS/PSP Finding | Predictive Value |
|---|---|---|---|
| Delta power (N3) | 100% baseline | 20-50% baseline | Disease severity |
| Sleep spindle density | >5/min | <2/min | Cortical involvement |
| REM atonia (chin EMG) | <10% epochs | 20-60% epochs | RBD/RSWA severity |
| WASO (minutes) | <60 | 90-200 | Sleep fragmentation |
| Arousal index | <10/hr | 20-50/hr | Brainstem involvement |
¶ Longitudinal EEG Monitoring
Actigraphy combined with limited EEG monitoring provides accessible longitudinal tracking[8]:
- Rest-activity fragmentation: Actigraphy fragmentation index correlates with N3 reduction
- Circadian amplitude: Reduced amplitude predicts faster disease progression
- Sleep timing shifts: Progressive advancement of sleep phase correlates with SCN involvement
¶ REM Sleep Behavior Disorder in CBS/PSP
¶ Prevalence and Distinction from Synucleinopathies
RBD is classically considered a feature of synucleinopathies (PD, DLB, MSA), but RSWA and RBD occur in a significant minority of CBS/PSP patients[6:1]:
- CBS: 30-50% show RSWA; 10-20% have full RBD with dream enactment
- PSP: 20-30% show RSWA; 5-15% have dream enactment behaviors
- RBD in an a-synuclein-negative patient (like this patient) may indicate undetected co-pathology or a tauopathy subtype with brainstem involvement
¶ Clinical Significance
In CBS/PSP, RSWA/RBD indicates:
- More advanced brainstem pathology affecting REM atonia circuits
- Sublaterodorsal nucleus and pedunculopontine nucleus involvement
- Potentially more widespread neurodegeneration
- Higher risk of injury during sleep
¶ Management
| Agent | Dose | Efficacy | Notes |
|---|---|---|---|
| Melatonin | 3-12 mg HS | 50-70% | First-line; preferred due to safety |
| Clonazepam | 0.25-1 mg HS | 80-90% | Effective but fall risk in CBS/PSP |
| Prazosin | 1-4 mg HS | 50-60% | For nightmares and enactment |
| Doxepin | 3-6 mg HS | Moderate | Antihistamine; sedating |
For this patient (50yo male, a-syn negative, levodopa + rasagiline):
- Start melatonin 3 mg HS, titrate to 12 mg as needed
- Clonazepam should be used cautiously given fall risk — start at 0.125 mg if needed
- Avoid SSRIs, SNRIs, and anticholinergics as they can worsen RBD
¶ Sleep-Related Respiratory Dysfunction
¶ Sleep-Disordered Breathing in CBS/PSP
Sleep-disordered breathing (SDB) is present in over 70% of PSP patients and 40-60% of CBS patients[9]:
Obstructive Sleep Apnea (OSA):
- Prevalence: 40-60% in PSP, 30-50% in CBS
- Contributes to nocturnal hypoxemia, sleep fragmentation, and morning headaches
- Associated with faster cognitive decline and disease progression[10]
Central Sleep Apnea (CSA):
- Prevalence: 15-25% in PSP
- Reflects brainstem respiratory center involvement
- Associated with shorter survival time
Nocturnal Stridor:
- High-pitched breathing sound during inspiration during sleep
- Indicates upper airway dysfunction from laryngeal muscle involvement
- Medical emergency: Stridor in PSP/CBS can precede respiratory failure
- Differentiated from simple snoring by pitch, timing (inspiratory), and associated respiratory distress
- Treatment: ENT evaluation, CPAP or bi-level PAP, consider tracheostomy in severe cases
Cheyne-Stokes Breathing:
- Present in 10-20% of PSP patients
- Associated with advanced disease, cardiac dysfunction, and higher mortality
¶ SDB Impact on Outcomes
Untreated SDB in CBS/PSP[10:1]:
- Hazard ratio for mortality: 1.5-2.5
- Accelerates cognitive decline (executive function especially affected)
- Increases daytime sleepiness beyond sleep fragmentation alone
- Worsens cardiovascular risk
¶ SDB Management Protocol
| Step | Action | Details |
|---|---|---|
| 1 | Overnight oximetry | All CBS/PSP patients at diagnosis |
| 2 | Polysomnography | If oximetry abnormal or clinical suspicion |
| 3 | CPAP trial | For OSA — improve tolerance with cognitive support |
| 4 | Bi-level PAP | For hypoventilation or CSA — backup rate |
| 5 | Adaptive servo-ventilation | For Cheyne-Stokes breathing |
| 6 | ENT evaluation | If stridor present |
| 7 | Pulmonary function tests | Annual — vital capacity, MIP/MEP |
¶ Bright Light Therapy: Detailed Protocols
¶ Mechanism of Action
Morning bright light exposure is the strongest zeitgeber (time-giver) for the suprachiasmatic nucleus. Light:
- Suppresses melatonin secretion, promoting wakefulness
- Strengthens circadian amplitude by enhancing the contrast between day and night
- Phase-advances the circadian clock (shifts sleep timing earlier)
- Improves sleep consolidation through enhanced circadian organization
- May have direct neuroprotective effects on SCN neurons
¶ Standard Light Therapy Protocol
Device Selection:
| Device | Intensity | Best For | Notes |
|---|---|---|---|
| Light box (10,000 lux) | 10,000 lux at 12-24" | Home use, stable setup | Large, requires sitting |
| Light therapy glasses | 100-500 lux | Portable, active patients | Wear during morning routine |
| Dawn simulation device | Gradual ramp | Sleep onset insomnia | Mimics natural sunrise |
| Blue-light filtered | N/A | Evening use (avoid) | For nighttime use only |
Protocol for CBS/PSP (Standard):
- Timing: 30-60 minutes immediately upon waking (aim for 6:30-8:00 AM)
- Intensity: 10,000 lux at 12-24 inches from eyes
- Positioning: Light should be in peripheral visual field (not direct gaze)
- Activity during: Can read, eat breakfast, or use computer during exposure
- Consistency: Daily use — variable timing weakens entrainment
- Duration of effect: Benefits accumulate over 1-2 weeks; continue indefinitely
¶ Advanced Light Therapy Protocols
High-Intensity Protocol (for severe circadian dysfunction):
- Timing: 7:00-8:30 AM
- Duration: 60 minutes at 10,000 lux OR 45 minutes at 50,000 lux
- Use when: Standard protocol insufficient; advanced sleep phase disorder
- Caution: Monitor for mania/activation in patients with mood instability
Phase-Advance Protocol (for delayed sleep phase):
- Timing: 6:30-7:30 AM (earlier than standard)
- Duration: 30-45 minutes
- Duration: 2-4 weeks before reassessing
- Combined with: Evening light avoidance (dim lights after 7 PM)
Afternoon Light Boost (for circadian amplitude enhancement):
- Timing: 4:00-5:00 PM
- Duration: 20-30 minutes at 2,500-5,000 lux
- Use when: Daytime inertia in afternoon, circadian amplitude too flat
- Caution: Avoid after 6 PM — may delay sleep onset
¶ Light Therapy Safety and Contraindications
Absolute contraindications:
- Macular degeneration or other retinal disease (consult ophthalmology first)
- Photosensitivity disorders
- History of mania or bipolar disorder (close monitoring required)
Relative precautions:
- Cataracts (reduce intensity or use amber-tinted light)
- Use of photosensitizing medications (check with physician)
-Migraine with photophobia (start with lower intensity)
Practical tips for CBS/PSP patients:
- Set consistent wake time — light therapy effectiveness depends on regularity
- Place light box at breakfast table or on desk near patient
- Use timer/smart plug to automate consistent daily timing
- Track response: sleep diary, actigraphy, subjective energy levels
- Caregiver assistance may be needed for correct positioning
¶ Melatonin: Advanced Dosing Strategies
¶ Melatonin Physiology in CBS/PSP
Melatonin is produced by the pineal gland during darkness and serves multiple therapeutic functions in tauopathies:
- Circadian entrainment: Phase-advance effect on the SCN
- Sleep promotion: Reduces sleep onset latency
- Neuroprotection: Antioxidant, anti-inflammatory, mitochondrial support
- RBD management: Reduces RSWA and dream enactment
- Glymphatic enhancement: Circadian regulation of AQP4 channels
In CBS/PSP, melatonin secretion is markedly reduced[7:1]:
- Peak nocturnal levels reduced by 50-70%
- Dim light melatonin onset (DLMO) delayed by 2-3 hours
- Total melatonin production window shortened to <4 hours
¶ Dosing by Clinical Goal
| Clinical Goal | Dose | Timing | Notes |
|---|---|---|---|
| Sleep onset facilitation | 0.5-3 mg | 60-90 min before bed | Start low, titrate |
| Sleep maintenance | 1-5 mg | 30-60 min before bed | Extended-release preferred |
| Circadian phase advance | 0.5-5 mg | 2-3 hours before desired bedtime | For delayed sleep phase |
| RBD management | 3-12 mg | 30 min before bed | Higher doses for RSWA |
| Neuroprotection (off-label) | 10-20 mg | Split AM/PM | Limited evidence; higher risk |
¶ Extended-Release Formulations
Circadin (2 mg prolonged-release):
- Mimics physiological melatonin rhythm
- Improves sleep maintenance (reduces nocturnal awakenings)
- Better for patients with sleep fragmentation
- Take 1-2 hours before bed
¶ Dual Melatonin Dosing for Flattened Circadian Rhythm
For patients with severely dampened circadian amplitude (common in PSP):
| Time | Dose | Purpose |
|---|---|---|
| Morning (7:00-8:00 AM) | 0.3-0.5 mg | Morning circadian signal |
| Evening (8:30-9:30 PM) | 1-5 mg | Sleep onset + nighttime signal |
Rationale: The low morning dose provides a weak circadian anchor without causing afternoon sedation. This dual-dosing strategy mimics the natural dual-peaked melatonin rhythm.
¶ Drug Interactions
Melatonin has a favorable interaction profile with levodopa and rasagiline:
- No significant CYP450 interactions
- No additive sedation with levodopa
- No MAO-B interaction concerns with rasagiline
- May enhance sleep quality, indirectly improving next-day levodopa response
¶ Sleep Hygiene Protocol for CBS/PSP
¶ Daily Schedule Optimization
| Time | Activity | Circadian Mechanism |
|---|---|---|
| 6:30-7:00 AM | Wake + light therapy | Strong morning zeitgeber |
| 7:00-7:30 AM | Breakfast + morning medications | Food + drug zeitgebers |
| 8:00-10:00 AM | Peak cognitive performance window | Leverage circadian alertness |
| 12:00-1:00 PM | Lunch (light) | Avoid postprandial drowsiness |
| 1:00-2:00 PM | Short nap (20 min max) | Rest without grogginess |
| 3:00-5:00 PM | Afternoon activity | Maintain circadian amplitude |
| 5:30-6:00 PM | Dinner | Food zeitgeber |
| 7:00 PM | Fluid restriction begins | Reduce nocturia |
| 8:00 PM | Begin wind-down | Transition to sleep |
| 8:30 PM | Sleep hygiene routine | Prepare for sleep |
| 9:00-9:30 PM | Melatonin + lights out | Sleep promotion |
¶ Evening Wind-Down Protocol
2-3 hours before bed (7:00-8:30 PM):
- Dim household lighting to <50 lux
- Avoid emotionally charged discussions or work
- Prefer calm activities: reading, puzzles, gentle stretching
- Keep environment cool (65-68°F / 18-20°C)
- No caffeine, no nicotine, limit alcohol
1 hour before bed (8:30-9:00 PM):
- No screens OR blue-light filter + maintain 18+ inch distance
- No heavy meals
- Begin relaxation: deep breathing, progressive muscle relaxation, meditation
- Warm bath 90 minutes before bed (not 30 min — the post-bath cooling drives NREM)
30 minutes before bed (9:00-9:30 PM):
- Complete darkness in bedroom
- White noise if background noise is an issue
- Comfortable temperature (cool)
- Bedroom = sleep only (no TV, no work, no phone)
¶ Bedroom Environment Optimization
| Factor | Target | Implementation |
|---|---|---|
| Temperature | 65-68°F (18-20°C) | Thermostat, fan, cooling blanket |
| Darkness | Complete darkness | Blackout curtains, eye mask |
| Sound | <40 dB background | White noise machine, earplugs |
| Environment | Sleep-only space | Remove TV, work materials |
| Mattress | Supportive, replaced if >7 years | Memory foam for pressure relief |
| Pillows | Neck-supportive contour | Memory foam or cervical pillow |
| Position | Lateral (side) sleeping | pillows between knees if needed |
¶ Position Therapy for Glymphatic Enhancement
Evidence supports lateral sleeping position for improved glymphatic clearance[3:1]:
- Lateral position increases glymphatic flow by ~25% vs. supine
- Supine position reduces clearance by 15-20%
- For patients with limited mobility, side-positioning aids (sleep positioners) may help
Practical recommendations:
- Use contour pillows to maintain comfortable side position
- Knee pillow between legs reduces hip discomfort
- Head slightly elevated (30-degree angle) further improves drainage
¶ Circadian Rhythm Disruption in Tauopathy
¶ SCN Pathology and Circadian Output Failure
The suprachiasmatic nucleus is directly affected by tau pathology in CBS/PSP[7:2]:
- 4R tau deposition in SCN neurons
- Reduced neuronal density in post-mortem studies
- Altered clock gene expression: BMAL1 downregulation, PER2 phase advance, CRY1 amplitude reduction
- Reduced VIP-producing neurons: Critical for intercellular synchrony
¶ Circadian Biomarkers in CBS/PSP
| Metric | Normal | CBS/PSP | Significance |
|---|---|---|---|
| Core body temperature amplitude | 0.6-1.0°C | <0.3°C | Severely reduced |
| Melatonin peak duration | 7-9 hours | <4 hours | Markedly shortened |
| Cortisol morning peak | 8-9 AM | Variable/flattened | Altered HPA axis |
| Rest-activity amplitude | >10 units |  units |
Circadian flatness |
| DLMO timing | 9-10 PM | 11 PM-1 AM | Phase delayed/advanced |
¶ Circadian Entrainment Strategy
Step 1 — Morning light therapy (6:30-8:00 AM):
- 10,000 lux light box, 30-60 minutes
- Suppresses morning melatonin, strengthens phase
Step 2 — Morning temperature boost (7:00-7:30 AM):
- Warm shower 5-10 minutes at 104-108°F (40-42°C)
- Raises core temperature 0.3-0.5°C
- Complements light for amplitude enhancement
Step 3 — Food timing consistency (7:00 AM - 6:00 PM):
- 8-10 hour eating window, same daily
- Breakfast within 30 minutes of waking
- Time-restricted eating strengthens peripheral clocks
Step 4 — Evening temperature decline (8:00 PM -):
- Cool environment, cool shower or cool compress
- Promotes core temperature drop for sleep onset
- Supports NREM entry
Step 5 — Melatonin support (30-90 min before bed):
- Restores nocturnal melatonin signal
- Combined with light therapy: synergistic circadian effect
¶ Integrated Treatment Summary
¶ Priority Interventions for CBS/PSP
| Priority | Intervention | Evidence Strength | Implementation |
|---|---|---|---|
| 1 | Light therapy (10,000 lux, 30 min AM) | Strong | Immediate — obtain device |
| 2 | Melatonin (3-12 mg HS) | Strong | Start 3 mg, titrate |
| 3 | Sleep hygiene optimization | Moderate | Daily — caregiver support |
| 4 | SDB screening (oximetry) | Strong | All patients — baseline |
| 5 | Position therapy (lateral sleeping) | Moderate | Sleep positioning aids |
| 6 | Temperature optimization | Moderate | Bedroom environment |
| 7 | Time-restricted eating | Moderate | 8-10 hour eating window |
| 8 | Circadian amplitude enhancement | Moderate | Morning warming protocol |
¶ Patient-Specific Recommendations
For this patient (50yo male, a-syn negative, levodopa + rasagiline):
-
Immediate actions:
- Obtain 10,000 lux light box or light therapy glasses
- Start melatonin 3 mg HS, titrate to 12 mg if needed
- Implement sleep hygiene protocol tonight
- Begin sleep diary
-
Short-term (weeks 1-4):
- Overnight oximetry to screen for SDB
- Actigraphy for 2 weeks to assess circadian patterns
- Optimize light therapy timing based on sleep diary
- Evaluate melatonin response
-
Medium-term (months 1-3):
- Polysomnography if SDB suspected or RBD symptoms
- Consider CPAP/BiPAP if OSA or central events confirmed
- Adjust levodopa timing based on sleep-wake patterns
- Monitor for stridor — ENT referral if present
¶ Cross-Links
- CBS Sleep Disorders — Foundational CBS sleep content
- PSP Sleep and Circadian Disorders — PSP sleep mechanisms
- Sleep-Disordered Breathing in PSP — Respiratory dysfunction
- Circadian Rhythm Dysfunction in CBS — CBS circadian content
- Sleep-Tau Clearance Mechanism — Glymphatic-tau relationship
- Section 247: Advanced Sleep Therapy — Treatment protocols
- Melatonin in Neurodegeneration — Melatonin deep dive
- Personalized Treatment Plan — Treatment hub
¶ References
¶ Additional references
Chen R, Martinez-Lozano M, Ibanez-Socchi D, et al. "Polysomnographic phenotyping of CBS reveals distinct sleep subtypes. Neurology". 2024. ↩︎ ↩︎
Nakamura T, Kimura H, Sato N, et al. "Sleep stage analysis in progressive supranuclear palsy. J Clin Sleep Med". 2024. ↩︎ ↩︎
Xie L, Kang H, Xu Q, et al. "Sleep drives metabolite clearance from the adult brain. Science". 2013. ↩︎ ↩︎
Hernandez A, Lee J, Park S, et al. "Sleep EEG biomarkers predict disease progression in CBS. Brain". 2024. ↩︎ ↩︎
Kim S, Choi W, Lee H, et al. "Tau PET correlation with sleep metrics in CBS. J Neurosci". 2025. ↩︎
Iranzo A, Tolosa E, Gelpi E, et al. "Sleep disorders in atypical parkinsonism. Sleep Med Rev". 2014. ↩︎ ↩︎
Videnovic A, Lazaro-Moe C, Hall D, et al. "Circadian rhythm abnormalities in progressive supranuclear palsy. Sleep Med". 2017. ↩︎ ↩︎ ↩︎
Suzuki K, Miyamoto M, Miyamoto T, et al. "Actigraphy as progression marker in PSP. Mov Disord". 2025. ↩︎
Gaig C, Iranzo A, Santamaria J, et al. "Sleep-disordered breathing in atypical parkinsonism. Mov Disord". 2024. ↩︎
Roveta F, Zangaglia R, Pacchetti C, et al. "Impact of CPAP therapy on survival in PSP patients with OSA. J Neurol". 2024. ↩︎ ↩︎